Maintaining a Hold: Casgevy Outperformance Balanced by Pipeline Execution Risks and Limited Valuation Upside

Tyler Van Buren, an analyst from TD Cowen, maintained the Hold rating on Crispr Therapeutics AG. The associated price target was raised to $45.00.

Tyler Van Buren has given his Hold rating due to a combination of factors, including a balanced view of near-term upside from Casgevy and the execution risks still embedded in the broader pipeline. He acknowledges that Casgevy uptake is outpacing earlier expectations, with stronger-than-modeled Q4 sales and a clearer path to growing revenue over the next two years, but believes this is largely reflected in the higher price target.

At the same time, he views the upcoming wave of clinical readouts across CTX310, zugo-cel, CTX611, and other early assets as a source of both potential value creation and uncertainty, given their early development stage and need to translate promising signals into registrational paths. As a result, he sees the current valuation as appropriately discounting pipeline optionality while leaving limited margin of safety, leading him to maintain a neutral stance rather than recommend adding or exiting the position.

According to TipRanks, Van Buren is a 5-star analyst with an average return of 19.1% and a 54.13% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and BridgeBio Pharma.

In another report released on February 3, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $50.00 price target.